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BACKGROUND: Mucous Membrane Pemphigoid, a new denomination of cicatricial pemphigoid, 
encompasses a group of chronic subepithelial autoimmune blistering diseases that predominantly affect 
the oral cavity and the eyes (conjunctivitis and symblepharon). 
CASE DETAILS: A rare case of Mucous Membrane Pemphigoid (MMP) in a human immunodeficiency 
virus (HIV) positive patient is discussed with clinicohistopathological presentation.  
CONCLUSION: Since our patient was HIV-positive and had lesions restricted to the oral mucosa with 
ocular involvement, only topical and intralesional steroids were preferred as the first line of treatment. 
Systemic corticosteroid therapy raises a concern regarding immunosuppression.  






MMP is autoimmune in nature and probably 
includes an autoantibody-induced, complement 
mediated sequestration of leukocytes with 
resultant cytokine and leukocyte enzyme release 
and detachment of the basal cells from the 
basement membrane zone, but there may also be 
complement-mediated cell lysis (1). MMP is 
characterized by junctional separation at the level 
of the basement membrane, causing a sub-basilar 
split.  
MMP affects women twice as frequently as it 
affects men. It is also called cicatricialpemphigoid 
as it is attributed to scarring (2). HIV-related 
MMP is rarely reported in the medical literature. 
We report a case of MMP in a male patient who 
was also diagnosed as HIV positive during 
investigations for MMP and did not show any 
other oral manifestations. 
We would also like to emphasize the need to 
investigate the immune status along with 
histopathology, immunofluorescence microscopy 
and Antibody Confirmation Tests for HIV, since 
HIV might have varying interactions with the 
immune system, which may lead to the 
development of autoimmune processes.  
 
CASE REPORT  
 
A forty-eight years old male patient reported with 
a chief complaint of painful ulcerations in his 
mouth and lip along with eye discomfort that had 
started before 10 days. He did not complain of the 
presence of any other systemic diseases or 
ongoing medical therapy, and did not report any 
changes in the skin or genital areas and related 
family history at the reporting date. The patient 
had normal physical and mental development with 
normal gait. 
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Clinical assessment: Oral examination revealed 
large ulcerations formed after the rupture of bulla 
involving upper left buccal vestibule and mucosa 
surrounded by epithelial sloughing (Figure 1). 
Superficial, hemorrhagic crusted ulcerations on 
upper and lower labial mucosa and irregular 
ulceration involving the floor of the mouth (Figure 
2) were well appreciable. A mild conjunctivitis 
with yellowish fibrinous slough and severe 
conjunctivitis were easily observed in the right 
and left eyes respectively (Figures 3). Further 
evaluation did not disclose any other lesions of 
buccal mucosa, perioral skin and genital areas. A 
mucosal biopsy was performed and the patient 
was recalled after five days for follow-up 
observation. However, on third day, the patient 
came with more extensive lesions on the left 
buccal mucosa, vestibule, upper and lower labial 
mucosa (Figure 4. It might be due to pressure on 
the normal mucosa applied during biopsy 
procedure (positive Nikolsky’s sign). The 
possibility of a drug-induced bullous eruption was 
effectively excluded in this patient because he did 
not use any drugs. 
The patient was treated with topical and 
intralesional corticosteroids (0.1% triamcinolone 
acetonide and dexamethasone 4mg/ml 
respectively). He was given instructions for   oral 
hygiene care with Chlorhexidine Mouthwash 
(0.2%) for five days and was referred to an 
ophthalmologist for conjunctival lesions. 
A significant improvement was noticed in the 
lesion size and symptoms after ten days, and 
thereafter, the patient did not return for follow-up. 
                                  
 
Figure 2: Showing lesion on floor of the mouth and lips 
 
 
Figure 3: Showing eye involvement 
 
 
Figure 4: Extensive lesions after three days of biopsy
Fig1: Clinical picture showing the lesion 






Figure 5: Photomicrograph of the lesion showing sub-
epithelial cleft 
 
Laboratory investigations: Routine blood 
investigations were found to be within normal 
range. Initially enzyme-linked immunosorbent 
assay (ELISA) and later Western blot were 
positive for HIV Antibody Confirmation Tests 
with 1180 CD4 cells /microlitre.     
Immunofluorescence examination: Immuno- 
fluorescence testing could not be done because of 
unavailability of preservative transport media 
during biopsy.  
Histopathological findings: Histopathology 
revealed the presence of Stratified squamous 
epithelium supported by fibrocellular connective 
tissue stroma and presence of subepithelial 
prominent areas of separation between the 
epithelium and connective tissue (Subepithelial 
cleft) with edematous connective tissue. Also 
dense infiltration of chronic inflammatory cells, 
predominantly the lymphocytes was seen 
(Figure5). There was also a presence of muscle 
tissue and adepocytes in the deeper portion of the 
tissue which was also infiltrated with 
inflammatory cells. Overall histopathological 
features were suggestive of mucous membrane 
pemphigoid.  
Differential diagnosis: The following differential 
diagnosis of blistering diseases was considered 
before final diagnosis: 
1. Erythema multiforme 
2. Pemphigus vulgaris 
3. Bullous pemphigoid 
4. Erosive Lichen Planus 




Mucous membrane pemphigoid has been known 
by many different names in the medical literature 
including benign mucous membrane pemphigoid, 
cicatricial (scarring) pemphigoid, and ocular 
cicatricialpemphigoid. A group of researchers in 
2002(1) determined that mucous membrane 
pemphigoid was the best designation for this 
group of disorders. The term "benign" mucous 
membrane pemphigoid was deemed inappropriate 
because of the potential for serious complications 
in cases where the lesions were very severe. The 
term "cicatricial" pemphigoid excluded affected 
individuals who do not develop scarring. Site-
specific terms such as "ocular" 
cicatricialpemphigoid excluded individuals with 
multiple site involvement (1). Since in this patient 
characteristic lesions are restricted only to the 
mucosa and the eye, it was diagnosed as MMP (2, 
3, 4). 
Pathogenesis of MMP probably includes an 
autoantibody-induced, complement mediated 
sequestration of leukocytes with resultant cytokine 
and leukocyte enzyme release and detachment of 
the basal cells from the basement membrane zone, 
but there may also be complement-mediated cell 
lysis. MMP is characterized by junctional 
separation at the level of the basement membrane, 
which gives rise to a sub-basilar split (5), which 
was observed in the present histopathological 
section. 
The association of immunodeficiency and 
autoimmunity in one patient is two sided clinical 
immune response. However, the reports of high 
frequency of auto antibodies in HIV-infected 
patients are increasing in the literature. 
Autoimmunity may develop during acute viral 
infection with normal to low CD4 counts (6), 
which may be a part of the nonspecific polyclonal 
B-cell stimulation secondary to interleukin (IL)-1 
and IL-2 released by HIV-infected macrophages 
(6,7). The frank loss of specific 
immunomodulatory CD4 T cells may allow the 
expansion of B-cell clone, which is responsible for 
the autoantibody formation (8).  
The actual pathogenesis and mechanism in 
development of mucous membrane pemphigoid 
secondary to HIV are still not confirmed. The 
possible mechanisms for autoimmune 
manifestations of HIV infection include the direct 





effect of HIV on endothelial, synovial, and other 
hematopoietic cells resulting in destruction of 
CD4 cells, increased cytotoxic cell activity and 
increased expression of auto-antigens (6). 
Molecular mimicry is one of the proposed 
mechanisms in the development of autoimmune 
disease. The exogenous infectious agent may have 
molecular similarity with a self-antigen and may 
therefore induce an autoimmune response (7, 8, 9).  
Pemphigus is similar in its clinical presentation 
with MMP, but it produces acantholysis with 
cleavage of the spinous cell layer and the vesicle 
is intraepithelial, whereas in MMP as a result of 
the separation of connective tissue from the 
epithelium the vesicle is subepithelial (10). 
Keratinocyte necrosis, intracellular edema in 
prickle layer, acanthosis and a perivascular 
inflammatory cell infiltrate with a thin basement 
membrane adhered to the epithelium are 
characteristic histopathological features of 
Erythema multiforme (10).  
In contrast to lichen planus, the inflammatory 
infiltrate is non-specific in nature comprising of 
lymphocytes, plasma cells neutrophils with few 
eosinophils. Patients with MMP rarely have 
circulating autoantibodies to the basement 
membrane zone components; thus, indirect 
immunofluorescence is usually not indicated as a 
diagnostic procedure.  
Treatment of MMP is based on the severity of 
symptoms and the site involved (1, 2). Patients 
with mild localized lesions may often benefit from 
topical steroids such as 
beclomethasonedipropionate, betamethasone, 
clobetasol propionate, fluocinomide. Patients with 
more extensive lesions can be prescribed systemic 
steroids like prednisolone (1). Other treatment 
regimens, which are effective in certain resistant 
cases, are immunosuppressive agents such as 
azathioprine, cyclophosphamide, cyclosporine and 
dapsone. Sulphononamides and tetracyclines can 
also be implemented (11, 12). In HIV-infected 
individuals, oral corticosteroid therapy raises a 
concern regarding increased immunosuppression. 
Therefore, it should not be used in continuous 
treatment. 
Since our patient was HIV-positive and had 
lesions restricted to the oral mucosa with ocular 
involvement, only topical and intralesional 
steroids were preferred as first-line treatment (1, 
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